
    
      MetIri is a two-stage single arm Phase II assessing the role of combination of metformin to
      irinotecan for colorectal cancer patients already treat with oxaliplatin, fluoropyrimidine,
      irinotecan and an anti-EGFr antibody if KRAS wild-type.
    
  